Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
Kathleen N. Moore(University of Oklahoma Medical Center), Paul DiSilvestro(Women & Infants Hospital of Rhode Island), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), Charlie Gourley(Edinburgh Cancer Research), Michael Friedländer(Prince of Wales Hospital), Alexandra Léary(Institut Gustave Roussy), Giovanni Scambia(Agostino Gemelli University Polyclinic), Carol Aghajanian(Memorial Sloan Kettering Cancer Center), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ana Oaknin(Hebron University), Amit M. Oza(Ontario Institute for Cancer Research), Ralph Bloomfield(AstraZeneca (United Kingdom)), Anne Floquet(Institut Bergonié), Nicoletta Colombo(University of Milano-Bicocca), J Liu(Dana-Farber Cancer Institute), GS Sonke(Edith Cowan University), B-G. Kim(Samsung Medical Center), E.S. Lowe(AstraZeneca (United States)), Cara Mathews(Brown University), W.H. Bradley(Froedtert Hospital), Alla Lisyanskaya(City Clinical Oncology Center)
Cited by 2
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k